Biorce, a Barcelona-based AI-powered healthcare tech startup specialized in applying artificial intelligence to the design and execution of clinical trials, raised $52.5 million in a fresh Series A funding round.
DST Global Partners led the latest investment round with participation from Norrsken VC, YZR Capital, Mustard Seed Maze and Endeavor Catalyst.
Including the new funding round, Biorce has raised $60 million in funding to date. With fresh funds, Biorce plans to expand its team to 250 employees by the end of 2026 and is planning to open a new R&D hub in Austin, Texas, strengthening its presence in the U.S. market and positioning the company closer to leading pharmaceutical, biotech, and innovation ecosystems.
Already in use across multiple therapeutic areas (including oncology, neurology, and rare diseases), Aika’s therapy-agnostic approach allows Biorce to scale the impact of AI across a wide range of clinical programs, setting a new industry standard for how trials are designed and managed.
Commenting on the funding news, Pedro Coelho, CEO of Biorce, said: “This $52 million round reflects both the scale of the problem we are addressing and the market’s confidence in our vision. Clinical trial delays and inefficiencies cost time, money, and ultimately lives.”
“Our mission is to make trials faster, more reliable, and more accessible, so patients can benefit from new treatments sooner. The speed at which we have raised capital since our last round in July 2025 is a strong validation of our technology, our team, and the impact we can generate,” added Pedro Coelho.
Over the past 12 months, Biorce has successfully closed €8.5 million in multiple seed investment rounds — €3.5 million in November 2024, followed by a €5 million seed extension from Norrsken VC in summer 2025— and now the $52.5 million series A round.